Safety, Tolerability, and Pharmacokinetics of the Broadly Neutralizing Human Immunodeficiency Virus (HIV)-1 Monoclonal Antibody VRC01 in HIV-Exposed Newborn InfantsColeen K. Cunningham, Karin Nielsen‐Saines, Betsy Smith et al.|The Journal of Infectious Diseases|2019Cited by 62
Safety, immunogenicity, and transplacental antibody transport of conjugated and polysaccharide pneumococcal vaccines administered to pregnant women with HIV: a multicentre randomised controlled trialAdriana Weinberg, Petronella Muresan, Lauren Laimon et al.|The Lancet HIV|2021Cited by 12
Effect of Maternal Immunization With 10-Valent Pneumococcus Conjugate Vaccine (PCV-10), 23-Valent Pneumococcus Polysaccharide Vaccine, or Placebo on the Immunogenicity of PCV-10 in Human Immunodeficiency Virus–Exposed Uninfected Infants: A Randomized Clinical TrialMarisa Márcia Mussi‐Pinhata, Adriana Weinberg, S. M. Ward et al.|Clinical Infectious Diseases|2022Cited by 10
Immunogenicity of Conjugated and Polysaccharide Pneumococcal Vaccines Administered During Pregnancy or Postpartum to Women With HIVGeraldo Duarte, Adriana Weinberg, Petronella Muresan et al.|The Journal of Infectious Diseases|2021Cited by 4
The importance of methods for site performance evaluation in REPRIEVE, a longitudinal, global, multicenter trialEvelynne S. Fulda, Kathleen V. Fitch, Carl J. Fichtenbaum et al.|Contemporary Clinical Trials|2022Cited by 3